# Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects

> **NCT03464058** · PHASE1 · COMPLETED · sponsor: **Boston Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** BOS172767 tablets
- **DRUG:** BOS172767 liquid capsules
- **DRUG:** BOS172767 micronized capsules
- **DRUG:** BOS172767 immediate release capsules
- **DRUG:** BOS172767 matching placebo capsules
- **DRUG:** BOS172767 matching placebo tablets
- **DRUG:** Rabeprazole

## Key facts

- **NCT ID:** NCT03464058
- **Lead sponsor:** Boston Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-21
- **Primary completion:** 2018-10-09
- **Final completion:** 2018-10-10
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2020-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03464058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03464058, "Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03464058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*